Rayence Co., Ltd. (KOSDAQ:228850)
South Korea · Delayed Price · Currency is KRW 6,350.00
+110.00 (1.76%)
At close: Mar 20, 2026
Rayence Revenue
In the year 2025, Rayence had annual revenue of 114.72B KRW, down -8.63%. Rayence had revenue of 29.13B in the quarter ending December 31, 2025, with 12.91% growth.
Revenue
114.72B
Revenue Growth
-8.63%
P/S Ratio
0.87
Revenue / Employee
512.16M
Employees
224
Market Cap
99.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 114.72B | -10.84B | -8.63% |
| Dec 31, 2024 | 125.56B | -17.42B | -12.18% |
| Dec 31, 2023 | 142.99B | -4.17B | -2.84% |
| Dec 31, 2022 | 147.16B | 12.59B | 9.36% |
| Dec 31, 2021 | 134.57B | 33.04B | 32.55% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Daewon Media | 302.05B |
| JCH Systems | 295.02B |
| Daehan Nupharm | 201.59B |
| Ibkimyoung | 119.49B |
| Daejung Chemicals & Metals | 104.05B |
| LabGenomics | 89.36B |
| Sam-A Pharm. | 76.66B |
| Korea New Network | 68.32B |